Atea Q3 net loss $42.0M ($0.53/share); HCV Phase 3 C-BEYOND fully enrolled by end-2025; HEV program launched

Atea Pharmaceuticals, Inc.

2025-Q3 EPS reported -$1.37 vs consensus -$0.45 ▼ miss (-205.3%)

Net loss of $42.0M ($0.53 diluted EPS) vs $31.2M ($0.37) in Q3 2024; R&D expenses rose to $38.3M.
Cash, equivalents and marketable securities $329.3M at Sep 30, 2025, down from $454.7M at Dec 31, 2024.
HCV Phase 3 C-BEYOND (US/Canada) enrollment on track for completion by end 2025; topline mid-2026.
New HEV development program with two lead candidates AT-587 and AT-2490; IND-enabling studies ongoing.
Completed $25M stock repurchase program: 7,673,793 shares at avg $3.26; shares outstanding 78,126,796.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.